[Enhancement of antitumor activity of mitomycin C against human breast carcinoma xenografts by pretreatment with KM 2210].

Abstract

Three human breast carcinoma xenografts, MCF-7, R-27 and T-61 serially transplanted into nude mice were treated with mitomycin C (MMC) alone, KM2210 (estra-1, 3, 5(10)-triene-3, 17 beta-diol, 3 benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acetate) alone and KM2210 followed by MMC. One hundred or 300 mg of KM2210 per kg were administered orally daily from Day 1 to 4 and MMC at the dose of 3 mg/kg was given ip on Day 5. The antitumor activity of MMC on these xenografts was enhanced by pretreatment with KM2210, suggesting a new combination chemo- and endocrine therapy of hormone-dependent human breast carcinomas.

• Authors: T Yamamoto, T Kubota, S Oka, K Josui, S Fujita, Y Arisawa, A Suto, S Inoue, M Kuzuoka, K Ishibiki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 17 Issue 1 Pg. 109-14 (Jan 1990) ISSN: 0385-0684 [Print] Japan
• PMID: 2105084 (Publication Type: English Abstract, Journal Article)

Chemical References

• Mitomycins
• Chlorambucil
• Estradiol
• Mitomycin
• bestrabucil

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy)
• Chlorambucil (administration & dosage, analogs & derivatives)
• Estradiol (administration & dosage, analogs & derivatives)
• Female
• Humans
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Mitomycin
• Mitomycins (administration & dosage)
• Neoplasm Transplantation
• Neoplasms, Hormone-Dependent (drug therapy)
• Transplantation, Heterologous